Radiation Oncology

Reshma Jagsi, MD, DPhil, highlights disparities in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.

The role of multimodal approaches such as FDG-PET imaging may require further investigation in patients with human papillomavirus–positive oropharyngeal cancer, according to Samuel Regan, MD.

At 1 and 2 years, patients with hepatocellular carcinoma and narrow surgical margins experienced encouraging recurrence-free survival rates following adjuvant radiotherapy in the phase 2 RAISE trial.

The FDA grants clearance to an oral immobilization stent designed to redirect radiation to the target tumor area for patients with head and neck cancer.

Findings from a secondary analysis of a phase 3 trial support stereotactic radiosurgery as a standard of care for those with brain metastases, although whole-brain radiotherapy may yield more local and distant control.

Adding adaptive radiation to chemotherapy may offer a novel approach to treating patients with advanced non–small cell lung cancer, according to Michael Steinberg, MD.

Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Findings from a phase 2 trial also show that there is no progression-free survival or overall survival benefit with lapatinib plus chemoradiotherapy in patients with non-human papillomavirus–related head and neck cancer.

A yoga intervention program in patients with head and neck cancer appears to correlate with significantly fewer feeding tube placements compared with those receiving usual care.

Data from the INTERLACE trial support induction chemotherapy prior to chemoradiation as a potential standard in locally advanced cervical cancer.

Diagnostic CT-enabled radiation therapy also reduces patient-reported time burden in the palliative setting.

Data from the FABREC trial support the use of hypofractionated postmastectomy radiotherapy in patients with breast cancer following implant-based reconstruction.

Real-world data suggest that the presence of pelvic lymphadenopathy should not be viewed as a contraindication to trimodality therapy in nonmetastatic clinically node-positive bladder cancer.

Jonathan Leeman, MD, indicates that the longer-follow is necessary to confirm late toxicities and disease control associated with adaptive radiotherapy in patients with prostate cancer.

Increasing radiation doses to the whole heart appear to correlate with higher risks of valvular disease, coronary artery disease, and heart failure in childhood cancer survivors.

Cutting out radiotherapy appears to be safe while improving quality of life in patients with POLE-mutated endometrial cancer.

The FDA requires data from an additional clinical trial to support the potential approval of avasopasem for managing radiation-induced severe oral mucositis in patients with head and neck cancer.

The addition of stereotactic radiotherapy to immune checkpoint inhibition appears safe but yields no significant survival benefit among patients with advanced solid tumors.

Fifteen-year follow-up data suggest the importance of considering the trade-offs between risks and benefits of active monitoring, prostatectomy, and radiotherapy for localized prostate cancer.

Data from the phase 3 NRG-RTOG 0631 may inform future research assessing spinal radiosurgery in the oligometastatic setting, according to an expert from Stony Brook University Medical Center.

The addition of short-term androgen deprivation to dose-escalated radiation therapy did not yield a significant difference in quality-of-life outcomes vs radiotherapy alone for those with intermediate-risk prostate cancer, according to an expert from Henry Ford Health Cancer.

In addition to granting fast track designation to RRx-001, the FDA accepts an investigational new drug application for the agent to reduce and/or prevent radiation- and chemotherapy-associated oral mucositis.

The 10-year cumulative local recurrence rate in patients with early breast cancer receiving accelerated partial breast irradiation with multi-catheter brachytherapy does not significantly differ from those receiving whole-breast irradiation following breast-conserving surgery.

Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.

Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.

Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.

An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.

An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.

The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.